Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
542.20B
Market cap542.20B
Price-Earnings ratio
26.05
Price-Earnings ratio26.05
Dividend yield
2.31%
Dividend yield2.31%
Average volume
8.36M
Average volume8.36M
High today
$232.00
High today$232.00
Low today
$224.59
Low today$224.59
Open price
$230.88
Open price$230.88
Volume
13.90M
Volume13.90M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $225.00. The company's market cap stands at 542.2B, with a P/E ratio of 26.05 and a dividend yield of 2.3%.

On 2026-06-01, Johnson & Johnson(JNJ) stock traded between a low of $224.59 and a high of $232.00. Shares are currently priced at $225.00, which is +0.2% above the low and -3.0% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 13.9M, against a daily average of 8.36M.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $149.04 at its lowest and $251.71 at its peak.

JNJ News

TipRanks 12h
Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

Johnson & Johnson announced results from the final analysis of the Phase 3 Proteus study showing the investigational use of apalutamide plus hormone therapy, gi...

Reuters 13h
Eugenio Suarez, JJ Bleday help Reds snap Braves' win streak - Reuters

...

Eugenio Suarez, JJ Bleday help Reds snap Braves' win streak - Reuters
24/7 Wall St. 16h
How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier By David Beren Published May 31, 1:41PM EDT...

How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

Analyst ratings

65%

of 26 ratings
Buy
65.4%
Hold
26.9%
Sell
7.7%

More JNJ News

Seeking Alpha 19h
J&J seeks expanded use for drug after positive head and neck cancer study

Johnson & Johnson (JNJ) reported new clinical trial results showing that its experimental subcutaneous formulation of amivantamab produced durable responses in...

J&J seeks expanded use for drug after positive head and neck cancer study
Nasdaq 20h
J&J Phase 3 : Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes

(RTTNews) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androge...

J&J Phase 3 : Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes
Nasdaq 2d
How to Recession-Proof Your Retirement Income Before Summer 2026

Key Points Recessions are a normal part of the economic cycle and can't be avoided. Investors can prepare for recessions by focusing on resilient sectors like...

How to Recession-Proof Your Retirement Income Before Summer 2026
24/7 Wall St. 2d
The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns By Drew Wood Published May 30, 9:18AM EDT Quick R...

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns
TipRanks 3d
J&J reports updated results from Phase 1/1b CHRYSALIS-2 study

Johnson & Johnson announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT in combination with LAZCLUZE in patients with...

Simply Wall St 3d
Johnson And Johnson MedTech Moves And What They Could Mean For Investors

Johnson & Johnson subsidiaries are integrating Gemtrack radiofrequency tracking technology from MinMaxMedical into DePuy Synthes orthopedic products. The compa...

Johnson And Johnson MedTech Moves And What They Could Mean For Investors
TipRanks 3d
J&J says FDA approves Tremfya label expansion

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to include evidence in the TREM...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.